Emergent Enters Into a New CDMO Agreement with Providence Therapeutics to Provide Fill/Finish Drug Product Manufacturing

02.13.2021

Emergent has entered into a new CDMO agreement with Providence Therapeutics to provide fill/finish drug product manufacturing services for their investigational mRNA vaccine candidate (PTX-COVID19-B) at its facility in Winnipeg, Manitoba, Canada. This is Emergent's 8th COVID-19 CDMO collaboration, and first outside of the U.S. in Canada.

We are proud to harness our industry-leading portfolio of CDMO services to support pharma & biotech innovators and governments/NGOs.

Emergent CDMO

COVID-19 In The News

09.14.2021

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies,...

01.25.2021

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™

GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021—Emergent BioSolutions Inc.(NYSE:EBS) (Emergent) andHumanigen, Inc....

09.01.2020

All Hands on Deck for Fill/Finish of Vaccines and Therapeutics

“Emergent has a long, successful history of working with the US government to develop, manufacture, and deliver safe and...